董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shlomo Yanai | 男 | Director | 63 | 12.50万美元 | 未持股 | 2016-04-29 |
| Mary Taylor Behrens | 女 | Director | 55 | 17.72万美元 | 未持股 | 2016-04-29 |
| Robert Flanagan | 男 | Director | 60 | 35.87万美元 | 未持股 | 2016-04-29 |
| Anthony Krizman | 男 | Director | 60 | 19.33万美元 | 未持股 | 2016-04-29 |
| Allan Oberman | 男 | Chief Executive Officer and Director | 58 | 242.97万美元 | 未持股 | 2016-04-29 |
| Michael Fekete | 男 | Director | 51 | 18.17万美元 | 未持股 | 2016-04-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean Brynjelsen | 男 | Executive Vice President, Business Development | 44 | 未披露 | 未持股 | 2016-04-29 |
| J. Frank Harmon | 男 | Executive Vice President, Global Operations | 61 | 未披露 | 未持股 | 2016-04-29 |
| Michael Ward | 男 | Chief Legal Officer and Corporate Secretary | 59 | 未披露 | 未持股 | 2016-04-29 |
| Albert Patterson | 男 | Executive Vice President, National Accounts and Corporate Development | 72 | 79.16万美元 | 未持股 | 2016-04-29 |
| Lorin Drake | 男 | Executive Vice President, Sales | 63 | 71.83万美元 | 未持股 | 2016-04-29 |
| Jonathon Singer | 男 | Executive Vice President and Chief Financial Officer | 52 | 84.40万美元 | 未持股 | 2016-04-29 |
| Allan Oberman | 男 | Chief Executive Officer and Director | 58 | 242.97万美元 | 未持股 | 2016-04-29 |
| Jeffrey Greve | 男 | Vice President, Controller | 41 | 未披露 | 未持股 | 2016-04-29 |
董事简历
中英对照 | 中文 | 英文- Shlomo Yanai
-
Shlomo Yanai，自2019年12月起担任董事会成员。Yanai先生拥有超过17年的企业领导经验，主要在制药行业。2007年至2012年，Yanai先生担任Teva Pharmaceutical Industries Ltd.的总裁兼首席执行官。在此之前，他从2002年到2006年担任Adama Industries的首席执行官。Yanai先生目前担任Lumenis Ltd.的董事会主席、Philip Morris的董事会成员、Moelis & Company的高级顾问。此前，他曾担任Rothschild Caesarea Foundation的副主席、Cambrex Corporation的董事会主席、Protalix Biotherapeutics、PDL BioPharma Inc.、Perrigo Company、Sagent Pharmaceuticals、Elisra、Bank Leumi Lelsreal和I.T.L. Optronics Ltd.的董事，以及W. R. Grace的董事会成员（2018-2021）。Yanai先生还在以色列国防军担任过各种领导职务。Yanai先生毕业于哈佛商学院（Harvard Business School）的AMP项目。他持有乔治华盛顿大学公共管理硕士学位和Tel Aviv大学学士学位，也是美国国防大学战争学院的毕业生。
Shlomo Yanai,has served on Board of Directors since December 2019. Mr. Yanai has more than 17 years of corporate leadership experience, primarily in the pharmaceutical industry. Mr. Yanai served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Prior to that, Mr. Yanai was the CEO of Adama Industries from 2002 to 2006. Mr. Yanai currently serves as the Chairman of the Board of Lumenis Ltd., a Board member at Philip Morris, and a senior advisor to Moelis & Company. Mr. Yanai previously served as Vice Chairman of the Rothschild Caesarea Foundation, Chairman of the Board of Cambrex Corporation and director of Protalix Biotherapeutics, PDL BioPharma Inc., Perrigo Company, Sagent Pharmaceuticals, Elisra, Bank Leumi Lelsreal, and I.T.L. Optronics Ltd. and a Board member of W. R. Grace from 2018-2021. Mr. Yanai also held various leadership positions in the Israel Defense Forces. Mr. Yanai is a graduate of Harvard Business School's AMP program. He holds a Master of Public Administration degree from George Washington University and a B.A. degree from Tel Aviv University and is also a graduate of the U.S. National Defense University – War College. - Shlomo Yanai，自2019年12月起担任董事会成员。Yanai先生拥有超过17年的企业领导经验，主要在制药行业。2007年至2012年，Yanai先生担任Teva Pharmaceutical Industries Ltd.的总裁兼首席执行官。在此之前，他从2002年到2006年担任Adama Industries的首席执行官。Yanai先生目前担任Lumenis Ltd.的董事会主席、Philip Morris的董事会成员、Moelis & Company的高级顾问。此前，他曾担任Rothschild Caesarea Foundation的副主席、Cambrex Corporation的董事会主席、Protalix Biotherapeutics、PDL BioPharma Inc.、Perrigo Company、Sagent Pharmaceuticals、Elisra、Bank Leumi Lelsreal和I.T.L. Optronics Ltd.的董事，以及W. R. Grace的董事会成员（2018-2021）。Yanai先生还在以色列国防军担任过各种领导职务。Yanai先生毕业于哈佛商学院（Harvard Business School）的AMP项目。他持有乔治华盛顿大学公共管理硕士学位和Tel Aviv大学学士学位，也是美国国防大学战争学院的毕业生。
- Shlomo Yanai,has served on Board of Directors since December 2019. Mr. Yanai has more than 17 years of corporate leadership experience, primarily in the pharmaceutical industry. Mr. Yanai served as President and Chief Executive Officer at Teva Pharmaceutical Industries Ltd. from 2007 to 2012. Prior to that, Mr. Yanai was the CEO of Adama Industries from 2002 to 2006. Mr. Yanai currently serves as the Chairman of the Board of Lumenis Ltd., a Board member at Philip Morris, and a senior advisor to Moelis & Company. Mr. Yanai previously served as Vice Chairman of the Rothschild Caesarea Foundation, Chairman of the Board of Cambrex Corporation and director of Protalix Biotherapeutics, PDL BioPharma Inc., Perrigo Company, Sagent Pharmaceuticals, Elisra, Bank Leumi Lelsreal, and I.T.L. Optronics Ltd. and a Board member of W. R. Grace from 2018-2021. Mr. Yanai also held various leadership positions in the Israel Defense Forces. Mr. Yanai is a graduate of Harvard Business School's AMP program. He holds a Master of Public Administration degree from George Washington University and a B.A. degree from Tel Aviv University and is also a graduate of the U.S. National Defense University – War College.
- Mary Taylor Behrens
-
Mary Taylor Behrens，2010年11月起担任公司董事会成员。她2003年2月起开始从事私人顾问工作，2004年11月起在咨询公司Newfane Advisors, Inc.担任总裁。此前，2001年2月至2003年1月，她担任Merrill Lynch Investment Managers美洲区主管或联合主管。1998年2月至2001年1月，她是Merrill Lynch & Co.高级副总裁，任人力资源部主管和执行委员会成员。2004年11月起她担任Manor Care, Inc.董事会成员，直至2007年12月公司被私有化。
Mary Taylor Behrens has served as a member of our Board since November 2010. Ms. Behrens has been engaged in private consulting since February 2003 and has held the position of President of Newfane Advisors, Inc., a consulting firm, since November 2004. Prior to that, from February 2001 until January 2003 Ms. Behrens served as Head or Co-Head of Merrill Lynch Investment Managers, Americas Region. From February 1998 until January 2001 Ms. Behrens was a Senior Vice President of Merrill Lynch & Co., serving as Head of Human Resources and a member of its Executive Committee. Ms. Behrens served as a member of the board of directors of Manor Care, Inc. from November 2004 until it went private in December 2007. Ms. Behrens holds a BA in Government from Georgetown University. - Mary Taylor Behrens，2010年11月起担任公司董事会成员。她2003年2月起开始从事私人顾问工作，2004年11月起在咨询公司Newfane Advisors, Inc.担任总裁。此前，2001年2月至2003年1月，她担任Merrill Lynch Investment Managers美洲区主管或联合主管。1998年2月至2001年1月，她是Merrill Lynch & Co.高级副总裁，任人力资源部主管和执行委员会成员。2004年11月起她担任Manor Care, Inc.董事会成员，直至2007年12月公司被私有化。
- Mary Taylor Behrens has served as a member of our Board since November 2010. Ms. Behrens has been engaged in private consulting since February 2003 and has held the position of President of Newfane Advisors, Inc., a consulting firm, since November 2004. Prior to that, from February 2001 until January 2003 Ms. Behrens served as Head or Co-Head of Merrill Lynch Investment Managers, Americas Region. From February 1998 until January 2001 Ms. Behrens was a Senior Vice President of Merrill Lynch & Co., serving as Head of Human Resources and a member of its Executive Committee. Ms. Behrens served as a member of the board of directors of Manor Care, Inc. from November 2004 until it went private in December 2007. Ms. Behrens holds a BA in Government from Georgetown University.
- Robert Flanagan
-
Robert Flanagan，2009年5月起担任公司董事会成员，2012年4月起担任首席董事。1989年起，他在Clark Enterprises, Inc.公司担任执行副总裁，负责并购、新投资机会的管理和开发。此前，他担任Baltimore Orioles, Inc.的财务主管、秘书、董事会成员。他也担任Martek Biosciences Corporation的董事会主席，以及Castle Brands, Inc.的董事会成员。他是一名在华盛顿执业的注册会计师。
Robert Flanagan has served as a member of our Board since May 2009 including as our lead director from April 2012 to June 2015 and as our chairman since June 2015. Mr. Flanagan has held the position of President of Clark Enterprises, Inc., since 2015 and was its Executive Vice President from 1989 to 2015. At Clark Enterprises, Mr. Flanagan oversees the acquisition, management and development of new investment opportunities. Prior to that, Mr. Flanagan served as the treasurer, secretary and a member of the board of directors of Baltimore Orioles, Inc. Mr. Flanagan has also served on the board of directors of Martek Biosciences Corporation, where he served as Chairman, and Castle Brands, Inc. and is a Certified Public Accountant licensed in Washington, D.C. Mr. Flanagan received a BS in Business Administration from Georgetown University and an MST from the American University School of Business. - Robert Flanagan，2009年5月起担任公司董事会成员，2012年4月起担任首席董事。1989年起，他在Clark Enterprises, Inc.公司担任执行副总裁，负责并购、新投资机会的管理和开发。此前，他担任Baltimore Orioles, Inc.的财务主管、秘书、董事会成员。他也担任Martek Biosciences Corporation的董事会主席，以及Castle Brands, Inc.的董事会成员。他是一名在华盛顿执业的注册会计师。
- Robert Flanagan has served as a member of our Board since May 2009 including as our lead director from April 2012 to June 2015 and as our chairman since June 2015. Mr. Flanagan has held the position of President of Clark Enterprises, Inc., since 2015 and was its Executive Vice President from 1989 to 2015. At Clark Enterprises, Mr. Flanagan oversees the acquisition, management and development of new investment opportunities. Prior to that, Mr. Flanagan served as the treasurer, secretary and a member of the board of directors of Baltimore Orioles, Inc. Mr. Flanagan has also served on the board of directors of Martek Biosciences Corporation, where he served as Chairman, and Castle Brands, Inc. and is a Certified Public Accountant licensed in Washington, D.C. Mr. Flanagan received a BS in Business Administration from Georgetown University and an MST from the American University School of Business.
- Anthony Krizman
-
Anthony Krizman，2010年7月担任公司董事会成员。2012年7月起，他担任私募投资公司Drake House Capital LLC的主席。此前，2010年6月30日起至退休，他担任PricewaterhouseCoopers, LLP（PwC）的保证合伙人。此外，他在PwC的职责包括：中西部地区风险管理领导、PwC品质保证委员会成员，西北俄亥俄州业务管理合伙人。在他在PwC任职的32年里，拓为客户提供很多问题的建议，包括私募的准备和发行、首次上市发行、arbanes-Oxley报告要求的执行、主要收购相关的尽职调查，以及业务单元的剥离等。他在管理年度财务报表和内部控制审计方面，以及公司在医疗保健、消费性包装品、汽车及服务行业等战略特别项目上，拥有丰富经验。他是一名注册会计师。
Anthony Krizman has served as a member of our Board since July 2010. Mr. Krizman has served as the Chairman of Drake House Capital LLC, a private investment firm, since July 2012. Prior to that, Mr. Krizman held the position of Assurance Partner at PricewaterhouseCoopers, LLP “PwC” through June 30 2010 when he retired. In addition, his responsibilities at PwC included Midwest Region Risk Management Leader, PwC Assurance Quality Board Member and Managing Partner, Northwest Ohio Practice. During his 32-year tenure at PwC, Mr. Krizman advised his clients on a substantial number of issues including: preparation for and execution of private placements and initial public offerings, implementation of Sarbanes-Oxley reporting requirements, and due diligence relating to major acquisitions and carve-outs of business units in divestitures. Mr. Krizman is a Certified Public Accountant. Mr. Krizman received a BS in Accounting and an MBA from Indiana University. - Anthony Krizman，2010年7月担任公司董事会成员。2012年7月起，他担任私募投资公司Drake House Capital LLC的主席。此前，2010年6月30日起至退休，他担任PricewaterhouseCoopers, LLP（PwC）的保证合伙人。此外，他在PwC的职责包括：中西部地区风险管理领导、PwC品质保证委员会成员，西北俄亥俄州业务管理合伙人。在他在PwC任职的32年里，拓为客户提供很多问题的建议，包括私募的准备和发行、首次上市发行、arbanes-Oxley报告要求的执行、主要收购相关的尽职调查，以及业务单元的剥离等。他在管理年度财务报表和内部控制审计方面，以及公司在医疗保健、消费性包装品、汽车及服务行业等战略特别项目上，拥有丰富经验。他是一名注册会计师。
- Anthony Krizman has served as a member of our Board since July 2010. Mr. Krizman has served as the Chairman of Drake House Capital LLC, a private investment firm, since July 2012. Prior to that, Mr. Krizman held the position of Assurance Partner at PricewaterhouseCoopers, LLP “PwC” through June 30 2010 when he retired. In addition, his responsibilities at PwC included Midwest Region Risk Management Leader, PwC Assurance Quality Board Member and Managing Partner, Northwest Ohio Practice. During his 32-year tenure at PwC, Mr. Krizman advised his clients on a substantial number of issues including: preparation for and execution of private placements and initial public offerings, implementation of Sarbanes-Oxley reporting requirements, and due diligence relating to major acquisitions and carve-outs of business units in divestitures. Mr. Krizman is a Certified Public Accountant. Mr. Krizman received a BS in Accounting and an MBA from Indiana University.
- Allan Oberman
-
Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London. - Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
- Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.
- Michael Fekete
-
Michael Fekete，2013年7月起担任公司董事会成员。2009年起，他担任资本市场、并购、公司日常策略方面的独立公司顾问。2005至2009年，他担任Wells Fargo / Wachovia Securities常务董事，以及西海岸医疗保健投资银行业务主管。此前，他在CIBC World Markets, Oppenheimer & Co., Inc.， 以及L.F. Rothschild & Co., Inc.等公司投资银行部工作。他是私营控股特种制药公司DFB Pharmaceuticals的董事，也是Symetis SA的董事，这是一家私营控股公司，为心脏瓣膜疾病患者研发微创心脏瓣膜置换疗法。
Michael Fekete joined our board of directors in July 2015. Mr. Fekete has served as an independent corporate advisor specializing in capital markets, mergers and acquisitions and general corporate strategy since 2009. From 2005 through 2009 Mr. Fekete was a Managing Director and Head of West Coast Healthcare Investment Banking for Wells Fargo / Wachovia Securities acquired by Wells Fargo in December 2008. From 1986 to 2005 Mr. Fekete worked as an investment banker at CIBC World Markets, Oppenheimer & Co., Inc., and L.F. Rothschild & Co., Inc., where he focused on clients in the medical device, pharmaceutical and biotechnology sectors. Mr. Fekete is a director of DFB Pharmaceuticals, LLC, a privately held company with operating and investing activities in the pharmaceutical sector. Mr. Fekete earned his B.S. in business administration from The Pennsylvania State University. - Michael Fekete，2013年7月起担任公司董事会成员。2009年起，他担任资本市场、并购、公司日常策略方面的独立公司顾问。2005至2009年，他担任Wells Fargo / Wachovia Securities常务董事，以及西海岸医疗保健投资银行业务主管。此前，他在CIBC World Markets, Oppenheimer & Co., Inc.， 以及L.F. Rothschild & Co., Inc.等公司投资银行部工作。他是私营控股特种制药公司DFB Pharmaceuticals的董事，也是Symetis SA的董事，这是一家私营控股公司，为心脏瓣膜疾病患者研发微创心脏瓣膜置换疗法。
- Michael Fekete joined our board of directors in July 2015. Mr. Fekete has served as an independent corporate advisor specializing in capital markets, mergers and acquisitions and general corporate strategy since 2009. From 2005 through 2009 Mr. Fekete was a Managing Director and Head of West Coast Healthcare Investment Banking for Wells Fargo / Wachovia Securities acquired by Wells Fargo in December 2008. From 1986 to 2005 Mr. Fekete worked as an investment banker at CIBC World Markets, Oppenheimer & Co., Inc., and L.F. Rothschild & Co., Inc., where he focused on clients in the medical device, pharmaceutical and biotechnology sectors. Mr. Fekete is a director of DFB Pharmaceuticals, LLC, a privately held company with operating and investing activities in the pharmaceutical sector. Mr. Fekete earned his B.S. in business administration from The Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Sean Brynjelsen
Sean Brynjelsen，他一直担任我们的执行副总裁，负责商业开发（2016年4月以来）。加入Sagent公司之前，他曾担任Akorn, Inc.（他于2007年加入该公司）的高级副总裁，负责全球商业开发，担任新商业开发主管。加入Akorn公司之前，他曾担任Hospira International、Baxter Healthcare Corporation的多种职务，并不断被提拔。他持有the University of Notre Dame的工商管理硕士学位、the University of Illinois的生物化学科学学士学位的和科学硕士学位。
Sean Brynjelsen has served as our Executive Vice President, Business Development, since April 2016. Prior to joining Sagent, Mr. Brynjelsen served as Senior Vice President, Global Business Development of Akorn, Inc., which he joined in 2007 as their Director of New Business Development. Prior to joining Akorn, Mr. Brynjelsen held roles of increasing responsibility at Hospira International and Baxter Healthcare Corporation. He earned a master’s degree in business administration from the University of Notre Dame and holds a bachelor’s degree of science in biochemistry and a master’s degree in science from the University of Illinois.- Sean Brynjelsen，他一直担任我们的执行副总裁，负责商业开发（2016年4月以来）。加入Sagent公司之前，他曾担任Akorn, Inc.（他于2007年加入该公司）的高级副总裁，负责全球商业开发，担任新商业开发主管。加入Akorn公司之前，他曾担任Hospira International、Baxter Healthcare Corporation的多种职务，并不断被提拔。他持有the University of Notre Dame的工商管理硕士学位、the University of Illinois的生物化学科学学士学位的和科学硕士学位。
- Sean Brynjelsen has served as our Executive Vice President, Business Development, since April 2016. Prior to joining Sagent, Mr. Brynjelsen served as Senior Vice President, Global Business Development of Akorn, Inc., which he joined in 2007 as their Director of New Business Development. Prior to joining Akorn, Mr. Brynjelsen held roles of increasing responsibility at Hospira International and Baxter Healthcare Corporation. He earned a master’s degree in business administration from the University of Notre Dame and holds a bachelor’s degree of science in biochemistry and a master’s degree in science from the University of Illinois.
- J. Frank Harmon
J. Frank Harmon，2016年3月以来，他担任我们全球运营执行副总裁。加入Sagent之前2014年以来，他担任Nesher Pharmaceuticals USA（Zydus Pharmaceuticals的全资子公司）的运营副总裁。加入Nesher之前2006年以来，他曾担任Fresenius Kabi USA的首席运营官和执行副总裁。他获得Saint Louis University的工商管理硕士学位和Western Kentucky University的科学学士学位。
J. Frank Harmon has served as our Executive Vice President, Global Operations, since March 2016. Prior to joining Sagent, Mr. Harmon served as Vice President, Operations of Nesher Pharmaceuticals USA, a wholly-owned subsidiary of Zydus Pharmaceuticals, since 2014. Prior to joining Nesher, Mr. Harmon was Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, which he joined in 2006. He earned a master’s degree in business administration from Saint Louis University and holds a bachelor’s degree in science from Western Kentucky University.- J. Frank Harmon，2016年3月以来，他担任我们全球运营执行副总裁。加入Sagent之前2014年以来，他担任Nesher Pharmaceuticals USA（Zydus Pharmaceuticals的全资子公司）的运营副总裁。加入Nesher之前2006年以来，他曾担任Fresenius Kabi USA的首席运营官和执行副总裁。他获得Saint Louis University的工商管理硕士学位和Western Kentucky University的科学学士学位。
- J. Frank Harmon has served as our Executive Vice President, Global Operations, since March 2016. Prior to joining Sagent, Mr. Harmon served as Vice President, Operations of Nesher Pharmaceuticals USA, a wholly-owned subsidiary of Zydus Pharmaceuticals, since 2014. Prior to joining Nesher, Mr. Harmon was Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, which he joined in 2006. He earned a master’s degree in business administration from Saint Louis University and holds a bachelor’s degree in science from Western Kentucky University.
- Michael Ward
Michael Ward自公司首次公开募股以来便担任公司的董事。在公司首次公开募股之前，Ward先生自2006年的收购完成后都在STI 担任董事。Ward先生于2003年加入Bain Capital，公司，并担任着总经理、首席运营官和财务主管职务。在加入Bain Capital公司之前，Ward先生自1998年3月至2003年在Digitas公司担任总裁和首席执行官，至此之前，从1997年8月起，他在Digitas公司只担任副总裁。他在加入Digitas公司之前，在Bain & Company和PricewaterhouseCoopers有限责任公司分别度过了四年和九年的职业时光。
Michael Ward has served as our Chief Legal Officer and Corporate Secretary since April 1 2016 served as our Deputy General Counsel and Corporate Secretary from January to March 2016 and as our Deputy General Counsel from June through December 2015. Prior to joining the Company, Mr. Ward was Vice President and Assistant General Counsel of Global Compliance, Ethics & Litigation at CDK Global in 2014 to 2015. From 2007 to 2014 he was at ACCO Brands Corporation where he was its Vice President and Chief Litigation & Risk Counsel. At such time, he was also General Counsel for the Kensington Technology division of ACCO Brands. Prior to that, Mr. Ward was the Senior Vice President, General Counsel, and Corporate Secretary for Targus Group International, and held legal and executive roles at Bergen Brunswig Corporation and AmerisourceBergen Corporation. Mr. Ward received a BA in History and Economics at Albion College and a JD from Case Western Reserve University School of Law.- Michael Ward自公司首次公开募股以来便担任公司的董事。在公司首次公开募股之前，Ward先生自2006年的收购完成后都在STI 担任董事。Ward先生于2003年加入Bain Capital，公司，并担任着总经理、首席运营官和财务主管职务。在加入Bain Capital公司之前，Ward先生自1998年3月至2003年在Digitas公司担任总裁和首席执行官，至此之前，从1997年8月起，他在Digitas公司只担任副总裁。他在加入Digitas公司之前，在Bain & Company和PricewaterhouseCoopers有限责任公司分别度过了四年和九年的职业时光。
- Michael Ward has served as our Chief Legal Officer and Corporate Secretary since April 1 2016 served as our Deputy General Counsel and Corporate Secretary from January to March 2016 and as our Deputy General Counsel from June through December 2015. Prior to joining the Company, Mr. Ward was Vice President and Assistant General Counsel of Global Compliance, Ethics & Litigation at CDK Global in 2014 to 2015. From 2007 to 2014 he was at ACCO Brands Corporation where he was its Vice President and Chief Litigation & Risk Counsel. At such time, he was also General Counsel for the Kensington Technology division of ACCO Brands. Prior to that, Mr. Ward was the Senior Vice President, General Counsel, and Corporate Secretary for Targus Group International, and held legal and executive roles at Bergen Brunswig Corporation and AmerisourceBergen Corporation. Mr. Ward received a BA in History and Economics at Albion College and a JD from Case Western Reserve University School of Law.
- Albert Patterson
Albert Patterson，2012年8月起担任公司国民会计和公司发展部执行副总裁。2012年3月至8月担任公司运营部执行副总裁；2010年6月至2012年3月担任运营部高级副总裁。加入公司前，2004年9月至2010年6月，他担任专注于通用制药行业的医疗保健咨询公司Bert Patterson Group的首席执行官。此前，2003年7月至2004年8月，他担任专注于备用站点医疗行业的集团服务机构Excel Rx GSO的总裁和首席执行官。1997年7月至2003年7月，他担任Pharmacy副总裁，Contract Center of Excellence副总裁，以及全国医疗保健集团采购组织Premier, Inc.备用站点医疗保健和业务发展部副总裁。1988年2月至1997年7月，他担任Hospital Pharmacy董事，Office of Drug Product Management董事，以及美国退伍军人事务部是内部医药福利经理。他担任Loyola University医学中心附近的Ronald McDonald House董事会成员。他也在伊利诺伊州、威斯康星州、普渡大学等药学院担任教员，也是Midwestern University芝加哥药学院院长委员会成员。他获有University of Illinois药学院的药学学士学位。
Albert Patterson has served as our Executive Vice President, National Accounts and Corporate Development, since August 2012. Mr. Patterson served as our Executive Vice President, Operations, from March 2012 through August 2012 and as our Senior Vice President, Operations from June 2010 through March 2012. Prior to joining our company, from September 2004 to June 2010 Mr. Patterson held the position of Chief Executive Officer of The Bert Patterson Group, a healthcare consulting company focused on the generic pharmaceutical industry. Prior to that, Mr. Patterson worked for Excel Rx GSO, Premier, Inc., and the U.S. Department of Veterans Affairs. Mr. Patterson served as a member of the board of directors of the Ronald McDonald House near Loyola University Medical Center. Mr. Patterson has also served in faculty positions at Illinois, Wisconsin and Purdue Colleges of Pharmacy and as a member of the Dean’s committee at Midwestern University, Chicago College of Pharmacy. Mr. Patterson received a BS in Pharmacy from the University of Illinois, College of Pharmacy.- Albert Patterson，2012年8月起担任公司国民会计和公司发展部执行副总裁。2012年3月至8月担任公司运营部执行副总裁；2010年6月至2012年3月担任运营部高级副总裁。加入公司前，2004年9月至2010年6月，他担任专注于通用制药行业的医疗保健咨询公司Bert Patterson Group的首席执行官。此前，2003年7月至2004年8月，他担任专注于备用站点医疗行业的集团服务机构Excel Rx GSO的总裁和首席执行官。1997年7月至2003年7月，他担任Pharmacy副总裁，Contract Center of Excellence副总裁，以及全国医疗保健集团采购组织Premier, Inc.备用站点医疗保健和业务发展部副总裁。1988年2月至1997年7月，他担任Hospital Pharmacy董事，Office of Drug Product Management董事，以及美国退伍军人事务部是内部医药福利经理。他担任Loyola University医学中心附近的Ronald McDonald House董事会成员。他也在伊利诺伊州、威斯康星州、普渡大学等药学院担任教员，也是Midwestern University芝加哥药学院院长委员会成员。他获有University of Illinois药学院的药学学士学位。
- Albert Patterson has served as our Executive Vice President, National Accounts and Corporate Development, since August 2012. Mr. Patterson served as our Executive Vice President, Operations, from March 2012 through August 2012 and as our Senior Vice President, Operations from June 2010 through March 2012. Prior to joining our company, from September 2004 to June 2010 Mr. Patterson held the position of Chief Executive Officer of The Bert Patterson Group, a healthcare consulting company focused on the generic pharmaceutical industry. Prior to that, Mr. Patterson worked for Excel Rx GSO, Premier, Inc., and the U.S. Department of Veterans Affairs. Mr. Patterson served as a member of the board of directors of the Ronald McDonald House near Loyola University Medical Center. Mr. Patterson has also served in faculty positions at Illinois, Wisconsin and Purdue Colleges of Pharmacy and as a member of the Dean’s committee at Midwestern University, Chicago College of Pharmacy. Mr. Patterson received a BS in Pharmacy from the University of Illinois, College of Pharmacy.
- Lorin Drake
Lorin Drake，2012年8月起担任公司销售部副总裁。2012年3月至8月，担任公司全球销售和市场部副总裁，2006年5月至2012年3月，担任销售和市场部副总裁。加入公司前，1998至2006年5月，他担任American Pharmaceutical Partners销售高级主管和销售副总裁。此前，他在Fujisawa USA和Lyphomed担任各种销售相关职位。他获有Manchester College经济学学士学位。
Lorin Drake has served as our Executive Vice President, Sales, since January 2015. Mr. Drake served as our Corporate Vice President, Sales from August 2012 through January 2015 our Corporate Vice President, Sales and Marketing, from March 2012 through August 2012 and as our Vice President, Sales and Marketing from May 2006 through March 2012. Prior to joining our company, from 1998 to May 2006 Mr. Drake held the positions of Senior Director of Sales and Vice President of Sales of American Pharmaceutical Partners. Prior to that Mr. Drake held various sales related positions at Fujisawa USA and Lyphomed. Mr. Drake received a BS in Economics from Manchester College.- Lorin Drake，2012年8月起担任公司销售部副总裁。2012年3月至8月，担任公司全球销售和市场部副总裁，2006年5月至2012年3月，担任销售和市场部副总裁。加入公司前，1998至2006年5月，他担任American Pharmaceutical Partners销售高级主管和销售副总裁。此前，他在Fujisawa USA和Lyphomed担任各种销售相关职位。他获有Manchester College经济学学士学位。
- Lorin Drake has served as our Executive Vice President, Sales, since January 2015. Mr. Drake served as our Corporate Vice President, Sales from August 2012 through January 2015 our Corporate Vice President, Sales and Marketing, from March 2012 through August 2012 and as our Vice President, Sales and Marketing from May 2006 through March 2012. Prior to joining our company, from 1998 to May 2006 Mr. Drake held the positions of Senior Director of Sales and Vice President of Sales of American Pharmaceutical Partners. Prior to that Mr. Drake held various sales related positions at Fujisawa USA and Lyphomed. Mr. Drake received a BS in Economics from Manchester College.
- Jonathon Singer
Jonathon Singer，2011年9月起担任公司首席财务官，2012年3月被任命为执行副总裁和首席财务官。加入公司前，2006年10月至2011年9月，他担任Landauer公司高级副总裁、财务负责人、秘书及首席财务官。加入Landauer前，他担任Teleflex公司全球金融副总裁和医疗部首席财务官，他2004年加入该公司。此前，他在Cardinal Health Inc., R.R. Donnelly & Sons Company和KPMG LLP工作。他是一名在俄亥俄州执业的注册会计师，获有俄亥俄州Miami University工商管理学士学位，以及Northwestern University凯洛格管理研究生院管理学硕士学位。
Jonathon Singer has served as our Chief Financial Officer since September 2011 and was appointed Executive Vice President and Chief Financial Officer in March 2012. Prior to joining our company, from October 2006 to September 2011 Mr. Singer served as Senior Vice President, Treasurer, Secretary and Chief Financial Officer of Landauer, Inc. Prior to joining Landauer, Mr. Singer was Vice President of Global Finance, Chief Financial Officer of the Medical Segment, for Teleflex, Inc., which he joined in 2004. Prior to that, Mr. Singer worked for Cardinal Health Inc., R.R. Donnelley & Sons Company and KPMG LLP. Mr. Singer served as a certified public accountant licensed in Ohio, and received a BS in business administration from Miami University in Ohio and an MA in management from Northwestern University’s Kellogg Graduate School of Management.- Jonathon Singer，2011年9月起担任公司首席财务官，2012年3月被任命为执行副总裁和首席财务官。加入公司前，2006年10月至2011年9月，他担任Landauer公司高级副总裁、财务负责人、秘书及首席财务官。加入Landauer前，他担任Teleflex公司全球金融副总裁和医疗部首席财务官，他2004年加入该公司。此前，他在Cardinal Health Inc., R.R. Donnelly & Sons Company和KPMG LLP工作。他是一名在俄亥俄州执业的注册会计师，获有俄亥俄州Miami University工商管理学士学位，以及Northwestern University凯洛格管理研究生院管理学硕士学位。
- Jonathon Singer has served as our Chief Financial Officer since September 2011 and was appointed Executive Vice President and Chief Financial Officer in March 2012. Prior to joining our company, from October 2006 to September 2011 Mr. Singer served as Senior Vice President, Treasurer, Secretary and Chief Financial Officer of Landauer, Inc. Prior to joining Landauer, Mr. Singer was Vice President of Global Finance, Chief Financial Officer of the Medical Segment, for Teleflex, Inc., which he joined in 2004. Prior to that, Mr. Singer worked for Cardinal Health Inc., R.R. Donnelley & Sons Company and KPMG LLP. Mr. Singer served as a certified public accountant licensed in Ohio, and received a BS in business administration from Miami University in Ohio and an MA in management from Northwestern University’s Kellogg Graduate School of Management.
- Allan Oberman
Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.- Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
- Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.
- Jeffrey Greve
Jeffrey Greve，2011年10月起任公司副总裁和财务总监。他2011年2月加入公司，担任外部和技术报告董事。加入Sagent前，他担任PricewaterhouseCoopers LLP保险业务高级经理，他1996年加入该公司，任内部会计。他获得University of Notre Dame会计学专业学士学位，也是一名注册会计师。
Jeffrey Greve has served as our Vice President, Controller since October 2011. Mr. Greve joined the Company in February 2011 as our Director, External and Technical Reporting. Prior to joining Sagent, Mr. Greve was a Senior Manager in the Assurance practice of PricewaterhouseCoopers LLP, which he initially joined as a Staff Accountant in 1996. Mr. Greve received a BBA with a concentration in accountancy from the University of Notre Dame and is a Certified Public Accountant.- Jeffrey Greve，2011年10月起任公司副总裁和财务总监。他2011年2月加入公司，担任外部和技术报告董事。加入Sagent前，他担任PricewaterhouseCoopers LLP保险业务高级经理，他1996年加入该公司，任内部会计。他获得University of Notre Dame会计学专业学士学位，也是一名注册会计师。
- Jeffrey Greve has served as our Vice President, Controller since October 2011. Mr. Greve joined the Company in February 2011 as our Director, External and Technical Reporting. Prior to joining Sagent, Mr. Greve was a Senior Manager in the Assurance practice of PricewaterhouseCoopers LLP, which he initially joined as a Staff Accountant in 1996. Mr. Greve received a BBA with a concentration in accountancy from the University of Notre Dame and is a Certified Public Accountant.